Research

Trial of siltuximab, an anti-IL6 antibody for treatment of COVID-19

• https://clinicaltrials.gov/ct2/show/NCT04329650
• https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/

Direct delivery of anti-IL6 Mabs to the lungs

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

• https://clinicaltrials.gov/ct2/show/NCT04320615
• https://www.cell.com/cell-host-microbe/pdf/S1931-3128(20)30236-5.pdf

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

• https://clinicaltrials.gov/ct2/show/NCT04315298

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19

RT-PCR and IgM/IgG test kits now available

New assay to detect presence of IgM and IgG against SARS-CoV-2 virus with peripheral blood (i.e. fingersticks)

Antibody responses to SARS-CoV-2 in patients with COVID-19

Conducting trials with Ivermectin, repurposing an anti-parasite drug

• https://www.sciencedirect.com/science/article/pii/S0166354220302011

Zydus explores the biologicals route to treat novel Coronaviruswith long-acting Interferon alpha-2b

A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.

A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.

Idronoxil inhibits a key inflammatory pathway involved in a process known as a cytokine storm, which is associated with an abnormally excessive inflammatory response and is believed to be responsible for most deaths in patients with COVID-19 infection

• https://www.noxopharm.com/site/PDF/6ddda156-2885-4417-ba1f-9e520f1cb085/NoxopharmInvestigatingPotentialCOVID19Treatment
• https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext

Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

• https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=Ruxolitinib&cntry=&state=&city=&dist=&Search=Search

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)

MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

MesenCure was developed for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients. MesenCure consists of activated Mesenchymal Stromal Cells (“MSCs”) that are isolated from the adipose tissue of healthy donors.

• https://www.bonusbiogroup.com/index.php/news-media/press-releases/item/32-bonus-biogroup-has-initiated-a-preclinical-study-of-a-unique-drug-developed-for-the-treatment-of-life-threatening-respiratory-distress-in-corona-covid-19-patients-and-pneumonia

Replicating Viral Vector currenly in preclinical testing

• http://www.globenewswire.com/news-release/2020/02/26/1990820/0/en/Tonix-Pharmaceuticals-Announces-Research-Collaboration-with-Southern-Research-to-Develop-a-Potential-Vaccine-to-Protect-Against-New-Coronavirus-Disease-2019-COVID-19-Based-on-Horse.html

Non-human primate model of COVID-19 infection to explore therapies, vaccines and effect of age

UCSF Researchers Aim to Enroll One Million Individuals for Real-Time Epidemiology

Reseach of how SARS-CoV-2 hijacks human cells for its own replication

To develop prophylactic/therapeutic antibody preparations

Testing and Analysis of SARS-CoV-2 protective gear

Development of diagnostic tools for SARS-CoV-2

Exploring inflammation in murine model of SARS-CoV-2 infection and vaccine development